Literature DB >> 8517711

Penetration of cefprozil into tonsillar and adenoidal tissues.

W C Shyu1, J Reilly, D A Campbell, R B Wilber, R H Barbhaiya.   

Abstract

Penetration of cefprozil into tonsillar and/or adenoidal tissues was investigated for patients undergoing tonsillectomy and/or adenoidectomy. A total of 29 patients ranging in age from 2 to 14 years participated in the study. The tonsils and/or the adenoids were removed at times ranging from 0.33 to 3.17 h after oral administration of a dose of either 7.5 or 20 mg/kg of body weight. A blood sample was also collected as soon as the tissue sample was removed. Plasma, tonsil, and adenoid samples were analyzed for cis and trans isomers of cefprozil by high-performance liquid chromatographic assays. The concentrations of the cis isomer of cefprozil in plasma ranged from 0.60 to 9.87 micrograms/ml at the 7.5-mg/kg dose level and from 1.04 to 20.40 micrograms/ml at the 20-mg/kg dose level. The corresponding concentrations of the cis isomer in tonsil tissue ranged from 0.48 to 2.42 micrograms/g and from 1.00 to 4.29 micrograms/g, respectively. The corresponding concentrations of the cis isomer in adenoid tissue ranged from 0.40 to 4.20 micrograms/g and from 1.74 to 4.94 micrograms/g, respectively. The concentrations of the trans isomer were about 1/10 of those observed for the cis isomer. The median ratios of the cefprozil concentration in tonsillar tissue to that in plasma were 0.37 and 0.47 for patients receiving a 7.5- or a 20-mg/kg oral dose of cefprozil, respectively. The corresponding median ratios for the adenoidal tissue were 0.46 and 0.82, respectively. The cefprozil concentrations in either the tonsillar or the adenoidal tissue at both dose levels over 3.17 h after dosing are much higher than the MICs for common pathogens which cause pharyngitis or tonsillitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517711      PMCID: PMC187928          DOI: 10.1128/AAC.37.5.1180

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Concentrations of cefpodoxime in plasma and tonsillar tissue after a single oral dose of cefpodoxime proxetil.

Authors:  P Gehanno; J M Andrews; F Ichou; E Sultan; B Lenfant
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

2.  In vitro activity of BMY-28100 against common isolates from pediatric infections.

Authors:  R K Scribner; M I Marks; B D Finkhouse
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

4.  In vitro activity of BMY-28100, a new oral cephalosporin.

Authors:  G M Eliopoulos; E Reiszner; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  [Experimental and clinical studies of cefotiam for the treatment of otorhinolaryngological infections].

Authors:  S Furuta; E Obata; Y Hanamure; K Fukuda; K Fukami; M Ohyama
Journal:  Jpn J Antibiot       Date:  1983-10

7.  [Clinical study of ceftizoxime suppositories in acute suppurative otitis media in children and tissue concentration of ceftizoxime in the palatine tonsil after administration of ceftizoxime suppositories].

Authors:  H Kinoshita; S Baba; Y Mori; K Suzuki; J Shimada; T Maruo; H Ito
Journal:  Jpn J Antibiot       Date:  1985-10

8.  [Transport of cefotetan into the otorhinolaryngeal tissues].

Authors:  Y Fujimaki; S Kawamura; R Sugita
Journal:  Jpn J Antibiot       Date:  1983-06

9.  Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans.

Authors:  W C Shyu; V R Shah; D A Campbell; R B Wilber; K A Pittman; R H Barbhaiya
Journal:  J Clin Pharmacol       Date:  1992-09       Impact factor: 3.126

10.  [Pharmacokinetics and clinical studies of cefmetazole in the otorhinolaryngological field].

Authors:  K Wada; S Baba; T Hatano; K Murai; H Kinoshita; I Takimoto; T Nomura; M Naito; S Iwata; T Nishimura; A Takasu; T Sekiya; K Miyagawa; M Tsukiyama; H Ito; Y Suzuki; J Hondoh; M Noda; K Umeda; T Maruo
Journal:  Jpn J Antibiot       Date:  1982-05
  10 in total
  6 in total

Review 1.  Optimum treatment of streptococcal pharyngitis.

Authors:  F Scaglione; G Demartini; M M Arcidiacono; J P Pintucci
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 2.  Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 4.  Cefprozil: a review.

Authors:  Sumit Bhargava; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

Review 5.  Redefining the management of pediatric tonsillopharyngitis with cefprozil.

Authors:  Nameet Jerath; Ganesh Shetty
Journal:  Indian J Pediatr       Date:  2007-12       Impact factor: 1.967

Review 6.  Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis.

Authors:  J M McCarty
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.